Autosomal Dominant Polycystic Kidney Clinical Trial
Official title:
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
Verified date | October 2023 |
Source | The Rogosin Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a proven safety profile with mechanisms of action that can counter the disease progression. The purpose of this study is to investigate whether drinking increased amounts of water (water loading) might slow down polycystic kidney growth or kidney function decline. Water loading can cause the suppression of a pathway that causes fluid buildup and cyst growth. High water intake has been safely used in the clinical setting, such as in the case of kidney stone therapy. New York State tap water is widely available and safe, making it highly cost-effective as well.
Status | Completed |
Enrollment | 10 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - pre-existing diagnosis of Autosomal Dominant Polycystic Kidney Disease - estimated glomerular filtration rate of 40 ml/min or greater - urine osmolality > 400 mOsm/L Exclusion Criteria: - estimated glomerular filtration rate less than 40 ml/min - low blood sodium levels - syndrome of inappropriate diuretic hormone - use of thiazide diuretics or selective serotonin reuptake inhibitors (SSRIs) - use of tolvaptan, another vasopressin receptor antagonist, vasopressin agonists or dDAVP - contraindications to magnetic resonance imaging (MRI) (pacemakers, defibrillators, implanted electronic devices, metallic foreign body) |
Country | Name | City | State |
---|---|---|---|
United States | The Rogosin Institute | New York | New York |
Lead Sponsor | Collaborator |
---|---|
The Rogosin Institute | Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in total kidney volume, as measured from magnetic resonance imaging | Total kidney volumes will be measured before and after the period of high water intake. Kidney volume growth with high water intake will be compared to baseline kidney volume growth. | 18 months | |
Secondary | Kidney function change | Blood creatinine levels will be measured and compared before and after the high water intake period. | 18 months | |
Secondary | Change in urine and blood markers of response to high water intake | Blood and urine biomarkers of response to high water intake will be measured before and after the period of high water intake. | 18 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Recruiting |
NCT03596957 -
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
Recruiting |
NCT05500157 -
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
|
N/A | |
Recruiting |
NCT04111692 -
A Prospective Observational Study of Foam Sclerotherapy .
|
||
Recruiting |
NCT04907799 -
Daily Caloric Restriction in ADPKD
|
N/A | |
Completed |
NCT05401409 -
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
Terminated |
NCT03749447 -
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
|
Phase 3 | |
Recruiting |
NCT05228574 -
Treatment of Vascular Stiffness in ADPKD
|
Phase 4 | |
Completed |
NCT04908462 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03858439 -
Dietary Intervention in ADPKD on Tolvaptan
|
N/A | |
Recruiting |
NCT06391450 -
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
|
Phase 4 | |
Recruiting |
NCT05478083 -
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
|
Phase 2 | |
Recruiting |
NCT05996731 -
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
|
N/A | |
Recruiting |
NCT06193616 -
Outcome of ADPKD With Octreotide LAR
|
||
Completed |
NCT05646420 -
Thyroid Hormones in ADPKD
|
N/A | |
Completed |
NCT03366337 -
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
|
Phase 2 | |
Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |